Tirzepatide Launch Timing Uncertainty
Product launch awaiting CRL (Complete Response Letter) clearance from regulator; expected this calendar year but no fixed timeline. NC-1 filing deadline is end-October, too late for new customers.
SHAILY / Q1-FY26 / risks
Keep the risk register visible.
Shaily Engineering Plastics · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
US Export Exposure to Tariff/Geopolitical Risk
US accounts for ~16% of revenue across consumer and industrial segments. Management noted fluid situation with tariff uncertainty and expects clarity in 60-90 days.
Machine Capacity Constraint in Pen Assembly Equipment
Global assembly machine manufacturers (ATS, EMA, Micron, etc.) have no free capacity available. Customers need to plan well in advance; potential bottleneck for industry-wide capacity ramp-up.
Oral GLP1 tablets vs. Injectables — 20-25% Market Share Risk
Oral semaglutide (Orforglipron) expected to capture 20-25% of GLP1 market; price cuts starting January 2026. Management argues injectables will dominate (75-80% share) due to superior bioavailability (oral is 1/10th as effective) and cost dynamics.